Evidence map›Paper›PMID 25126694›Full record

ArticleACS chemical biology2014

Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication.

Sourav Mukherjee, Warren S Weiner, Chad E Schroeder, Denise S Simpson, Alicia M Hanson, Noreena L Sweeney, Rachel K Marvin, Jean Ndjomou, Rajesh Kolli, Dragan Isailovic and 2 more

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 91 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Organoselenium compounds beyond antioxidants.Future medicinal chemistry · 2024
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Sourav MukherjeeDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53211, United States.
Warren S Weiner
Chad E Schroeder
Denise S Simpson
Alicia M Hanson
Noreena L Sweeney
Rachel K Marvin
Jean Ndjomou
Rajesh Kolli
Dragan Isailovic
Frank J Schoenen
David N Frick
University of Wisconsin–Milwaukee · USUniversity of Kansas · USUniversity of Toledo · US

Funding

University of Kansas Specialized Chemistry CenterU54HG005031 · NHGRI · UNIVERSITY OF KANSAS LAWRENCE · PI AUBE, JEFFREY · 2008 to 2013
$21.5M
Antiviral potential of helicase inhibitorsR01AI088001 · NIAID · UNIVERSITY OF WISCONSIN MILWAUKEE · PI FRICK, DAVID N · 2010 to 2012
$1.1M
NHGRI NIH HHS U54 HG005031NIAID NIH HHS R01 AI088001
6 · The paper itself

Abstract

The hepatitis C virus (HCV) nonstructural protein 3 (NS3) is both a protease, which cleaves viral and host proteins, and a helicase that separates nucleic acid strands, using ATP hydrolysis to fuel the reaction. Many antiviral drugs, and compounds in clinical trials, target the NS3 protease, but few helicase inhibitors that function as antivirals have been reported. This study focuses on the analysis of the mechanism by which ebselen (2-phenyl-1,2-benzisoselenazol-3-one), a compound previously shown to be a HCV antiviral agent, inhibits the NS3 helicase. Ebselen inhibited the abilities of NS3 to unwind nucleic acids, to bind nucleic acids, and to hydrolyze ATP, and about 1 μM ebselen was sufficient to inhibit each of these activities by 50%. However, ebselen had no effect on the activity of the NS3 protease, even at 100 times higher ebselen concentrations. At concentrations below 10 μM, the ability of ebselen to inhibit HCV helicase was reversible, but prolonged incubation of HCV helicase with higher ebselen concentrations led to irreversible inhibition and the formation of covalent adducts between ebselen and all 14 cysteines present in HCV helicase. Ebselen analogues with sulfur replacing the selenium were just as potent HCV helicase inhibitors as ebselen, but the length of the linker between the phenyl and benzisoselenazol rings was critical. Modifications of the phenyl ring also affected compound potency over 30-fold, and ebselen was a far more potent helicase inhibitor than other, structurally unrelated, thiol-modifying agents. Ebselen analogues were also more effective antiviral agents, and they were less toxic to hepatocytes than ebselen. Although the above structure-activity relationship studies suggest that ebselen targets a specific site on NS3, we were unable to confirm binding to either the NS3 ATP binding site or nucleic acid binding cleft by examining the effects of ebselen on NS3 proteins lacking key cysteines.

Indexed as

AntioxidantsAntiviral AgentsAzolesCarcinoma, HepatocellularCell ProliferationDEAD-box RNA HelicasesElectrophoretic Mobility Shift AssayHepacivirusHepatitis CHumansHydrolysisIsoindolesKineticsLiver NeoplasmsModels, MolecularNucleic AcidsAntioxidantsAntiviral AgentsAzolesDEAD-box RNA HelicasesebselenIsoindolesNS3 protein, hepatitis C virusNucleic AcidsNucleoside-TriphosphataseOrganoselenium CompoundsSerine EndopeptidasesViral Nonstructural ProteinsViral Proteases

Identifiers

PMID25126694
PMCPMC4201343
OpenAlexW2072013113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.